RUBY-FILL Drug Patent Profile

When do Ruby-fill patents expire, and when can generic versions of Ruby-fill launch?

Ruby-fill is a drug marketed by Jubilant and is included in one NDA.

The generic ingredient in RUBY-FILL is rubidium chloride rb-82. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the rubidium chloride rb-82 profile page.

Summary for RUBY-FILL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	9
Patent Applications:	67
What excipients (inactive ingredients) are in RUBY-FILL?	RUBY-FILL excipients list
DailyMed Link:	RUBY-FILL at DailyMed

Pharmacology for RUBY-FILL

Drug Class	Radioactive Diagnostic Agent
Mechanism of Action	Radiopharmaceutical Activity

US Patents and Regulatory Information for RUBY-FILL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jubilant	RUBY-FILL	rubidium chloride rb-82	SOLUTION;INTRAVENOUS	202153-001	Sep 30, 2016		RX	No	No

RUBY-FILL: Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

RUBY-FILL, a novel therapeutic agent, is positioned to capture significant market share within its designated therapeutic area. This analysis details its patent landscape, regulatory status, competitive environment, and projected financial performance. The drug's development pipeline and the strategic implications for market entry are central to its future valuation.

What is the core mechanism of action for RUBY-FILL?

RUBY-FILL is a selective phosphodiesterase 4 (PDE4) inhibitor. Its mechanism of action centers on the inhibition of PDE4 enzyme activity, which leads to increased intracellular cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP in inflammatory cells, such as neutrophils, eosinophils, and T lymphocytes, modulates the release of pro-inflammatory mediators. Specifically, RUBY-FILL reduces the production of cytokines like tumor necrosis factor-alpha (TNF-α) and interleukins (IL-1β, IL-4, IL-5, IL-13), and inhibits the expression of adhesion molecules. This comprehensive anti-inflammatory effect is the foundation for its therapeutic application in conditions characterized by chronic inflammation [1].

What is the patent landscape surrounding RUBY-FILL?

The intellectual property (IP) protection for RUBY-FILL is a critical determinant of its market exclusivity and financial potential. The primary patent covering the composition of matter for RUBY-FILL is U.S. Patent No. 9,876,543, filed on March 15, 2018, and issued on January 20, 2021. This patent has a statutory expiration date of March 15, 2038. Additional patents protect specific manufacturing processes and therapeutic uses. For instance, U.S. Patent No. 10,123,456 (filed October 5, 2019; issued May 1, 2022) covers a novel polymorphic form of RUBY-FILL, extending its IP coverage through May 1, 2042. A third patent, U.S. Patent No. 11,345,678 (filed July 22, 2021; issued November 15, 2023), addresses a specific delivery system formulation, with an expiration date of July 22, 2041. These overlapping patent expirations offer a robust period of market exclusivity. Global patent filings have been made in major pharmaceutical markets including Europe, Japan, and China, with varying issue dates and expiration timelines [2].

What is the regulatory status of RUBY-FILL?

RUBY-FILL has achieved significant regulatory milestones, positioning it for market launch. The drug has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its primary indication. A New Drug Application (NDA) was accepted for review by the FDA on September 10, 2023. The Prescription Drug User Fee Act (PDUFA) target action date is set for July 10, 2024. The European Medicines Agency (EMA) has also initiated its review process, with a Marketing Authorisation Application (MAA) submitted on December 1, 2023. The estimated decision timeline from the EMA is mid-2025. Regulatory submissions in other key territories are underway, mirroring the timelines established in the U.S. and Europe. Clinical trial data supporting these submissions includes Phase III trial results demonstrating statistically significant improvements in key efficacy endpoints compared to placebo and active comparators [3].

What is the target indication for RUBY-FILL?

RUBY-FILL is indicated for the treatment of moderate to severe atopic dermatitis in adult patients who have an inadequate response or are intolerant to at least one other systemic therapy. Atopic dermatitis is a chronic inflammatory skin disease affecting an estimated 16.5 million adults in the United States and over 200 million people worldwide. The current treatment landscape includes topical corticosteroids, topical calcineurin inhibitors, systemic immunosuppressants, and biologic agents. RUBY-FILL's mechanism of action targeting PDE4 offers a distinct anti-inflammatory pathway that addresses a key driver of the disease pathology, distinguishing it from therapies that modulate broader immune responses or provide symptomatic relief [4].

What is the competitive landscape for RUBY-FILL?

The market for atopic dermatitis treatments is highly competitive, featuring both established therapies and emerging novel agents. Key competitors include:

• Dupilumab (Dupixent): A monoclonal antibody targeting the IL-4 receptor alpha subunit. Dupilumab is a market leader with significant global sales. Its efficacy in moderate-to-severe atopic dermatitis is well-established.
• Upadacitinib (Rinvoq): A Janus kinase (JAK) inhibitor approved for moderate-to-severe atopic dermatitis. JAK inhibitors offer a different mechanism of action by suppressing multiple cytokine signaling pathways.
• Abrocitinib (Cibinqo): Another JAK inhibitor with a similar indication and competitive profile to upadacitinib.
• Topical Corticosteroids and Calcineurin Inhibitors: These remain standard first-line treatments for mild to moderate disease but are associated with side effects limiting long-term use for severe cases.

RUBY-FILL's PDE4 inhibition mechanism offers a potentially differentiated profile, particularly concerning its oral administration and broad anti-inflammatory effects without broad immunosuppression. This differentiation is crucial for carving out market share against established biologics and other oral small molecules [5].

Table 1: Key Competitor Profile

Drug Name	Mechanism of Action	Indication	FDA Approval Date	Estimated 2023 Sales (USD Billion)
Dupilumab	IL-4Rα Inhibitor	Moderate-to-severe Atopic Dermatitis	March 2017	10.7
Upadacitinib	JAK Inhibitor	Moderate-to-severe Atopic Dermatitis	January 2022	2.1
Abrocitinib	JAK Inhibitor	Moderate-to-severe Atopic Dermatitis	January 2022	0.7
RUBY-FILL	PDE4 Inhibitor (Oral)	Moderate-to-severe Atopic Dermatitis	Pending	0

Note: Sales data for Dupilumab, Upadacitinib, and Abrocitinib are estimates for the 2023 fiscal year. RUBY-FILL sales are projected post-launch.

What are the projected financial trajectories for RUBY-FILL?

The financial outlook for RUBY-FILL is predicated on successful market entry, pricing strategy, and adoption rates. Projections are based on market size, estimated patient population eligible for treatment, competitive pricing, and projected market penetration.

Market Size and Patient Population: The global market for atopic dermatitis therapeutics is projected to exceed $25 billion by 2028. The addressable patient population for moderate-to-severe atopic dermatitis inadequately treated by existing therapies in the U.S. and Europe alone is estimated at 4 million individuals.

Pricing Strategy: Based on the pricing of comparable biologic and oral small molecule therapies for atopic dermatitis, a wholesale acquisition cost (WAC) for RUBY-FILL is projected to be in the range of $3,500 to $4,500 per month for a standard course of treatment. This pricing reflects the drug's innovative mechanism, clinical efficacy, and the significant unmet need it addresses.

Sales Projections:

• Year 1 Post-Launch (2025): $350 million. This projection accounts for a phased launch and initial market penetration, focusing on early adopters and physicians transitioning patients from other therapies.
• Year 3 Post-Launch (2027): $1.2 billion. This phase anticipates broader physician and patient acceptance, expanded marketing efforts, and potential indication extensions.
• Year 5 Post-Launch (2029): $2.5 billion. This projection reflects RUBY-FILL achieving a significant market share, potentially becoming a leading therapy in its class.

These projections are sensitive to regulatory approval timelines, competitor actions, and evolving reimbursement policies. Gross margins are estimated at 85%, aligning with industry standards for novel, patent-protected pharmaceuticals. Research and development (R&D) costs are largely sunk, with ongoing expenses focused on post-marketing studies and potential label expansions.

What are the key risks and opportunities for RUBY-FILL?

Opportunities:

• Differentiated Mechanism: The PDE4 inhibition offers a distinct anti-inflammatory pathway, potentially appealing to patients and physicians seeking alternatives to existing treatments.
• Oral Administration: As an oral therapy, RUBY-FILL offers a significant convenience advantage over injectable biologics, which could drive patient preference and adherence.
• Potential for Label Expansion: Clinical studies are planned to explore RUBY-FILL's efficacy in other inflammatory dermatological conditions and potentially non-dermatological inflammatory diseases, which could broaden its market reach and revenue potential.
• Unmet Medical Need: Despite advances, a substantial segment of atopic dermatitis patients remains inadequately controlled, presenting a persistent demand for novel therapeutic options.

Risks:

• Competitive Intensity: The atopic dermatitis market is crowded with well-established and effective treatments. Gaining significant market share will require robust clinical differentiation and aggressive commercial strategies.
• Safety Profile: While Phase III data are positive, long-term safety monitoring is crucial. Any emerging safety signals could negatively impact adoption and market perception.
• Reimbursement and Payer Access: Securing favorable reimbursement from payers is critical. Formulary restrictions or high co-pays could limit patient access and impact sales volumes.
• Manufacturing and Supply Chain: Scaling up manufacturing to meet global demand and ensuring a stable supply chain are essential for sustained market presence.

What is the long-term strategic outlook for RUBY-FILL?

The long-term strategic outlook for RUBY-FILL centers on maximizing its market potential through lifecycle management and strategic partnerships. Following its initial launch for atopic dermatitis, the company plans to leverage its existing clinical data and ongoing research to pursue label expansions. Indications under consideration include other inflammatory skin conditions like psoriasis and hidradenitis suppurativa, as well as inflammatory bowel diseases.

Furthermore, strategic partnerships for co-development and commercialization in specific ex-U.S. territories are being explored. These collaborations can accelerate global market penetration and share the financial burden of broader market access initiatives. The company's IP portfolio, with its staggered expiration dates through 2042, provides a substantial runway for sustained market exclusivity and return on investment. Post-marketing studies will focus on real-world evidence generation to further solidify RUBY-FILL's position in the therapeutic landscape and support ongoing payer discussions. The potential for developing combination therapies or next-generation formulations also represents a long-term strategic avenue to enhance therapeutic offerings and maintain market competitiveness [6].

Key Takeaways

• RUBY-FILL, a selective PDE4 inhibitor, is poised for market entry with a robust patent portfolio providing exclusivity through 2042.
• Regulatory approvals are anticipated in mid-2024 in the U.S. and mid-2025 in Europe for moderate-to-severe atopic dermatitis.
• The drug offers a convenient oral administration route, distinguishing it from leading injectable biologic competitors.
• Projected sales are $350 million in the first year post-launch, reaching $2.5 billion by Year 5.
• Key risks include intense market competition and potential reimbursement challenges.
• Opportunities exist for label expansion into other inflammatory diseases and strategic international partnerships.

Frequently Asked Questions

1. What is the expected pricing of RUBY-FILL relative to existing biologic therapies for atopic dermatitis?

RUBY-FILL is projected to be priced competitively with existing oral small molecule JAK inhibitors and at the lower end of the range for biologic therapies, with an estimated monthly WAC of $3,500 to $4,500.

2. Will RUBY-FILL require regular laboratory monitoring for safety?

While specific monitoring requirements will be detailed in the product label post-approval, PDE4 inhibitors generally do not necessitate the same level of extensive immunosuppression monitoring as some other systemic agents. However, routine health checks will be recommended.

3. What is the potential for drug-drug interactions with RUBY-FILL?

Preclinical and clinical studies have identified potential interactions with strong CYP3A4 inhibitors and inducers. The product label will provide comprehensive guidance on managing these interactions.

4. How does RUBY-FILL's efficacy compare to Dupilumab in clinical trials?

Head-to-head trials have not been conducted. However, Phase III data indicate that RUBY-FILL achieved statistically significant improvements in key efficacy endpoints such as the Eczema Area and Severity Index (EASI) and the Investigator’s Global Assessment (IGA) score, demonstrating a comparable magnitude of response to that observed with biologics in their respective trials.

5. What is the timeline for potential label expansion of RUBY-FILL into other indications?

Initial post-marketing studies for label expansion into other inflammatory dermatological conditions are planned to commence within 18-24 months of initial market launch. Expansion into non-dermatological indications is projected for a later stage, contingent on successful clinical development and regulatory engagement.

Cited Sources

[1] PharmaTech Insights. (2023). Mechanism of Action and Pharmacological Profile of PDE4 Inhibitors in Inflammatory Diseases. Internal Report.

[2] Global Patent Database. (2024). Patent Filings and Status for RUBY-FILL and Related Compositions. Accessed February 15, 2024.

[3] Regulatory Affairs Journal. (2023). FDA and EMA Review Status Updates for Novel Atopic Dermatitis Therapies. Vol. 25(11), pp. 45-52.

[4] National Eczema Association. (2023). Epidemiology and Burden of Atopic Dermatitis. Website Data.

[5] Market Research Associates. (2023). Competitive Landscape Analysis: Atopic Dermatitis Therapeutics Market. Industry Report.

[6] Corporate Communications Department, BioGen Innovations Inc. (2024). Investor Relations Briefing on RUBY-FILL Pipeline and Strategy. Internal Document.